Key Slides on HCV Treatment Considerations for an Aging MSM With HIV

Review this patient case of an older man with HIV and newly diagnosed HCV reinfection, including relevant data on rates of HCV reinfection and management guidelines for HCV in MSM.
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 255 KB
Released: November 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Concise Clinical Care Options (CCO) presentation by Darrell H. S. Tan, MD, FRCPC, PhD, on approved and guideline-recommended oral HIV PrEP regimens

person default Darrell H. S. Tan, MD, FRCPC, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 29, 2021 Expired: July 28, 2022

Vlog from Clinical Care Options (CCO) and Dr. Jehan Budak demonstrating HIV-ASSIST to guide ART selection in a HTE patient with HIV. Review of NRTI, NNRTI, PI, INSTI mutations, and more.

Jehan Budak, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Physician Assistants: maximum of 0.25 hour of AAPA Category ICME credit ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 27, 2021 Expired: July 26, 2022

ZeNix: bedaquiline, pretomanid, plus varying doses and durations of linezolid in patients with highly resistant TB, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 26, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue